Cadus Pharmaceutical
Executive Summary
ImClone Systems spinoff raises $8 mil. in initial financing completed Aug. 8. Investors include Icahn Holding Corp. and Global Health Sciences Fund. NYC-based Cadus is researching signal transduction pathways as targets for potential inflammatory, cardiovascular and neuro-psychiatric therapies.